Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 19, 2021

View Archived Issues

Phase II data reported for cabozantinib in type I neurofibromatosis with PNs

BET inhibitors synergize with BCL-2 or HDAC inhibitors in Waldenstrom macroglobulinemia

Grifols to begin clinical evaluation of new COVID-19 treatment

Biohaven presents focused analysis data from phase II/III study of troriluzole in AD

First patient dosed in phase II study of alisporivir in early-stage COVID-19

Eli Lilly initiates phase II study of LY-3462817 in rheumatoid arthritis

Enrollment opens in phase II study of vactosertib plus pembrolizumab in NSCLC

Murine model of SARS-CoV-2 infection developed via mRNA transfection of hACE2

Sobetirome and its prodrug show efficacy in models of EAE

LCP2 is a therapeutic target in lethal sepsis

Shanghai Institute of Materia Medica dicloses new hepatitis B virus inhibitors

New CDK9/cyclin T1 inhibitors discovered at Medshine Discovery

Preclinical data show SENS-401 reduces loss of residual hearing after cochlear implantation

Hangzhou Hertz Pharmaceutical patents casein kinase 1 isoform epsilon inhibitors

DMC recommends start of part 2 of COVA study of Sarconeos in COVID-19

Guangdong Newopp Biopharmaceuticals identifies mutant KRAS inhibitors

New JAK inhibitors synthesized at Guangzhou Innocare Pharma Tech

Phase I trial of LY-CovMab in China completes enrollment

Novel GPC3/CD47 bispecific antibody shows strong antitumor activity in HCC xenografts

HELP is on its way for herpetic stromal keratitis

Transgene gains clearance in France for phase I/IIa study of BT-001 for solid tumors

CRY1 unveiled as a hormone-induced tumorigenic factor in prostate cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...